Martin Gramatzki

University Hospital Schleswig-Holstein — Germany

Medicine · Health Sciences

56h-index11.5kcitations405works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(112), Multiple Myeloma Research and Treatments(94), Chronic Lymphocytic Leukemia Research(66), Lymphoma Diagnosis and Treatment(60), CAR-T cell therapy research(51)

Publications404 total

A novel Fc-optimized antibody-drug conjugate targeting CD7 for the therapy of T-cell acute lymphoblastic leukemia
2025Open Access
Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia
Blood·2024· 1 citedOpen Access
A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies
Blood·2024· 3 cited
A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 is Active in Preclinical Models of T-ALL
Klinische Pädiatrie·2024Open Access
Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease
Bone Marrow Transplantation·2023· 2 citedOpen Access
A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia
Blood·2023· 2 cited
Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells
Frontiers in Immunology·2023· 18 citedOpen Access
P-198 Impact of blocking the CD47 axis on phagocytosis of myeloma cells treated with CD38 antibodies and proteasome inhibitors
Clinical Lymphoma Myeloma & Leukemia·2023
P-199 Novel antibodies identified by phage display induce direct myeloma cell death
Clinical Lymphoma Myeloma & Leukemia·2023
Supplementary Figures from The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Data from The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Data from The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Figures from The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Data from Novel Bispecific Antibodies Increase γδ T-Cell Cytotoxicity against Pancreatic Cancer Cells
2023Open Access
Supplementary Methods from Novel Bispecific Antibodies Increase γδ T-Cell Cytotoxicity against Pancreatic Cancer Cells
2023Open Access
Supplementary Figures 1 - 7 from Novel Bispecific Antibodies Increase γδ T-Cell Cytotoxicity against Pancreatic Cancer Cells
2023Open Access
Supplementary Methods from Novel Bispecific Antibodies Increase γδ T-Cell Cytotoxicity against Pancreatic Cancer Cells
2023Open Access
Supplementary Figure Legends from Novel Bispecific Antibodies Increase γδ T-Cell Cytotoxicity against Pancreatic Cancer Cells
2023Open Access
Supplementary Figure Legends from Novel Bispecific Antibodies Increase γδ T-Cell Cytotoxicity against Pancreatic Cancer Cells
2023Open Access
Data from Novel Bispecific Antibodies Increase γδ T-Cell Cytotoxicity against Pancreatic Cancer Cells
2023Open Access
page 1 of 21Next →

Frequent Co-authors

Roland Repp(14), Thomas Valerius(10), Renate Burger(8), Hermann Einsele(7), Heinz Ludwig(6), Mario Boccadoro(6), Michèle Cavo(6), Evangelos Terpos(6), Pieter Sonneveld(6), Dietrich W. Beelen(6), Bernhard Stockmeyer(6), Meletios Α. Dimopoulos(5), Monika Engelhardt(5), Francesca Gay(5), Jan G. J. van de Winkel(5), Rainer Schwerdtfeger(4), Dietger Niederwieser(4), Ralph Wäsch(4), Alessandra Larocca(4), Martin Bornhäuser(4)